Tobam Boosts Stake in United Therapeutics Corporation $UTHR

Tobam lifted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 183.9% in the third quarter, HoldingsChannel.com reports. The fund owned 7,646 shares of the biotechnology company’s stock after acquiring an additional 4,953 shares during the quarter. Tobam’s holdings in United Therapeutics were worth $3,205,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. State of New Jersey Common Pension Fund D raised its position in United Therapeutics by 8.2% during the third quarter. State of New Jersey Common Pension Fund D now owns 15,147 shares of the biotechnology company’s stock valued at $6,350,000 after purchasing an additional 1,150 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of United Therapeutics by 4.0% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,564 shares of the biotechnology company’s stock valued at $1,494,000 after purchasing an additional 137 shares during the last quarter. HighTower Advisors LLC raised its holdings in shares of United Therapeutics by 14.5% during the 3rd quarter. HighTower Advisors LLC now owns 3,824 shares of the biotechnology company’s stock valued at $1,603,000 after buying an additional 483 shares in the last quarter. Weil Company Inc. lifted its position in United Therapeutics by 4.0% in the 3rd quarter. Weil Company Inc. now owns 5,408 shares of the biotechnology company’s stock worth $2,267,000 after buying an additional 207 shares during the last quarter. Finally, Florida Financial Advisors LLC bought a new stake in United Therapeutics in the 3rd quarter worth approximately $219,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Stock Down 0.5%

NASDAQ:UTHR opened at $473.66 on Monday. The company has a fifty day moving average of $486.02 and a 200 day moving average of $434.55. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $519.99. The firm has a market capitalization of $20.40 billion, a P/E ratio of 17.95, a P/E/G ratio of 2.52 and a beta of 0.85.

Insider Activity at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $479.91, for a total transaction of $10,797,975.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold 454,714 shares of company stock worth $219,909,558 over the last ninety days. Corporate insiders own 10.30% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on UTHR shares. Royal Bank Of Canada increased their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a research note on Wednesday, October 29th. HC Wainwright lifted their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Jefferies Financial Group reissued a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a research note on Wednesday, November 19th. Finally, UBS Group upped their price target on shares of United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $509.50.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.